Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High – Still a Buy?

Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $15.31 and last traded at $15.12, with a volume of 2903073 shares traded. The stock had previously closed at $15.16.

Takeda Pharmaceutical Trading Up 0.3 %

The business has a fifty day moving average price of $14.04 and a 200-day moving average price of $13.91. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The company has a market cap of $47.89 billion, a P/E ratio of 37.63, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

Institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at $40,000. BNP Paribas Financial Markets raised its holdings in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after acquiring an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after acquiring an additional 1,976 shares during the period. Finally, Erste Asset Management GmbH acquired a new stake in shares of Takeda Pharmaceutical during the 3rd quarter worth $52,000. Institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.